Table 1. . Metastasis evolution after 2 months of initial (1A) and subsequent (1B) T-DXd administration.
| Table 1A. Metastasis evolution after 2 months of initial T-Dxd administration. | |||||
|---|---|---|---|---|---|
| Lesion | Maximal diameter (mm) | % change | Measurable (>5 mm) | RANO-BM response | |
| Baseline | After T-Dxd (2 mo) | ||||
| 1 | 38 | 41.1 | 8.2 | † | † |
| 2 | 6.5 | 0 | ‐100.0 | X | CR |
| 3 | 2.4 | 0 | ‐100.0 | ||
| 4 | 9.5 | 0 | ‐100.0 | X | CR |
| 5 | 14.7 | 0 | ‐100.0 | X | CR |
| 6 | 8.5 | 8.4 | ‐1 | † , ‡ | † , ‡ |
| 7 | 7.6 | 0 | ‐100.0 | X | CR |
| 8 | 8.6 | 9.4 | 9.3 | † , ‡ | † , ‡ |
| 9 | 8.6 | 0 | ‐100.0 | X | CR |
| 10 | 1.8 | 0 | ‐100.0 | ||
| 11 | 9.6 | 0 | ‐100.0 | X | CR |
| 12 | 3.0 | 0 | ‐100.0 | ||
| 13 | 14.7 | 0 | ‐100.0 | X | CR |
| 14 | 8.1 | 0 | ‐100.0 | X | CR |
| 15 | 6.9 | 0 | ‐100.0 | X | CR |
| 16 | 2.5 | 0 | ‐100.0 | ||
| Table 1B. Metastasis evolution after 2 months of rescue T-Dxd administration. | |||||
|---|---|---|---|---|---|
| Lesion | Maximal diameter (mm) | % change | Measurable (>5 mm) | RANO-BM response | |
| Before T-Dxd | After T-Dxd (2 mo) | ||||
| 1 | 33.8 | 30.5 | ‐9.8 | † | † |
| 2 | 12.7 | 10.3 | ‐18.9 | X§ | SD |
| 3 | 8.7 | 6.4 | ‐26.4 | X | SD |
| 4 | 29.1 | 27.2 | ‐6.5 | † | † |
| 5 | 10.3 | 6.2 | ‐39.8 | X§ | PR |
| 6 | 9.2 | 8.2 | ‐10.9 | X§ | SD |
| 7 | 4.7 | 1.0 | ‐78.7 | ||
| 8 | 7.7 | 8.2 | 6.5 | X | SD |
| 9 | 9.9 | 0 | ‐100.0 | X§ | CR |
| 10 | 4.3 | 2 | ‐53.5 | ||
| 11 | 3.8 | 0 | ‐100.0 | ||
| 12 | 9.1 | 0 | ‐100.0 | X§ | CR |
†
Biopsy-proven to represent treatment effect and not recurrent metastatic disease.
‡
These two lesions subsequently enlarged and became confluent. Lesion 4 in Table 1B represents the confluence of lesions 6 & 8 in Table 1A. The remainder of lesions listed in Table 1B do not necessarily correspond to those in Table 1A.
§
Target lesions (those with the five largest diameters) for the purposes of intracranial response assessment.
CR: Complete response; mo: months; PR: Partial response; RANO-BM: Response Assessment in Neuro-Oncology Brain Metastases; SD: Stable disease; TDXd: Trastuzumab deruxtecan.